Latest & greatest articles for calcium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on calcium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on calcium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for calcium

81. Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness

Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness CADTH Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions There remains a paucity of good quality evidence to support the use of docusate

Health Technology Assessment (HTA) Database.2014

82. Neuromuscular disorders: prophylaxis and treatment guidelines for calcium and vitamin D for children and young people with neuromuscular disorders in the UK

Neuromuscular disorders: prophylaxis and treatment guidelines for calcium and vitamin D for children and young people with neuromuscular disorders in the UK Neuromuscular disorders: prophylaxis and treatment guidelines for calcium and vitamin D for children and young people with neuromuscular disorders in the UK | Great Ormond Street Hospital Navigation Search Search You are here Neuromuscular disorders: prophylaxis and treatment guidelines for calcium and vitamin D for children and young (...) people with neuromuscular disorders in the UK Neuromuscular disorders: prophylaxis and treatment guidelines for calcium and vitamin D for children and young people with neuromuscular disorders in the UK 1.0 Prophylaxis of vitamin D deficiency Prophylactic vitamin D should be given to those who are at are at risk of vitamin D deficiency. The following babies and children are at risk: Children with mobility and poor weight bearing ability ( ). Children with reduced exposure to sunlight (such as those

Great Ormond Street Hospital2014

83. Systematic review: Calcium channel blockers are effective as first line for tocolysis in the management of preterm labour

Systematic review: Calcium channel blockers are effective as first line for tocolysis in the management of preterm labour Calcium channel blockers are effective as first line for tocolysis in the management of preterm labour | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Calcium channel blockers are effective as first line for tocolysis in the management of preterm labour Article Text Therapeutics Systematic review Calcium channel blockers are effective as first line for tocolysis in the management of preterm labour Richard G Brown , David

Evidence-Based Medicine (Requires free registration)2014

84. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury.

Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. IMPORTANCE: Calcium-channel blockers are metabolized by the cytochrome P450 3A4 (CYP3A4; EC 1.14.13.97) enzyme. Blood concentrations of these drugs may rise to harmful levels when CYP3A4 activity is inhibited. Clarithromycin is an inhibitor of CYP3A4 and azithromycin is not, which makes comparisons between these 2 macrolide antibiotics useful in assessing clinically important drug interactions. OBJECTIVE (...) : To characterize the risk of acute adverse events following coprescription of clarithromycin compared with azithromycin in older adults taking a calcium-channel blocker. DESIGN, SETTING, AND PARTICIPANTS: Population-based retrospective cohort study in Ontario, Canada, from 2003 through 2012 of older adults (mean age, 76 years) who were newly coprescribed clarithromycin (n = 96,226) or azithromycin (n = 94,083) while taking a calcium-channel blocker (amlodipine, felodipine, nifedipine, diltiazem, or verapamil

JAMA2013

85. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation

Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation 24146170 2014 08 05 2014 09 30 2016 11 25 1468-3288 63 9 2014 Sep Gut Gut Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation. 1424-30 (...) 10.1136/gutjnl-2013-305523 Osteoporosis and fractures are frequently encountered in patients with Crohn's disease. In order to prevent fractures, treatment with bone protecting drugs appears warranted early in the course of bone disease when bone loss is not yet prominent. We therefore aimed to demonstrate a beneficial effect on bone density of the bisphosphonate risedronate in osteopenic Crohn's disease patients. This double-blind, placebo-controlled randomised trial of risedronate with calcium

EvidenceUpdates2013

86. Calcium Density of Coronary Artery Plaque and Risk of Incident Cardiovascular Events.

Calcium Density of Coronary Artery Plaque and Risk of Incident Cardiovascular Events. IMPORTANCE: Coronary artery calcium (CAC), measured by computed tomography (CT), has strong predictive value for incident cardiovascular disease (CVD) events. The standard CAC score is the Agatston, which is weighted upward for greater calcium density. However, some data suggest increased plaque calcium density may be protective for CVD. OBJECTIVE: To determine the independent associations of CAC volume

JAMA2013 Full Text: Link to full Text with Trip Pro

87. Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones

Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones 23929928 2013 11 08 2014 07 01 2016 12 15 1555-905X 8 11 2013 Nov Clinical journal of the American Society of Nephrology : CJASN Clin J Am Soc Nephrol Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. 1960-7 10.2215/CJN.01760213 Higher urinary uric acid (...) excretion is a suspected risk factor for calcium oxalate stone formation. Febuxostat, a xanthine oxidoreductase inhibitor, is effective in lowering serum urate concentration and urinary uric acid excretion in healthy volunteers and people with gout. This work studied whether febuxostat, compared with allopurinol and placebo, would reduce 24-hour urinary uric acid excretion and prevent stone growth or new stone formation. In this 6-month, double-blind, multicenter, randomized controlled trial

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

88. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis

Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta (...) -analysis Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, Lok CE, Fitchett D, Tsuyuki RT CRD summary This review concluded that non-calcium-based phosphate binders were associated with a decreased risk of all-cause mortality compared with calcium-based phosphate binders in patients with chronic kidney disease. This was a generally well-conducted review but the conclusions seem overly strong. Authors' objectives To update a prior meta-analysis that compared the effect of calcium

DARE.2013

89. Calcium polystyrene sulphonate powder for oral/rectal suspension (Sorbisterit) - treatment of hyperkalaemia

Calcium polystyrene sulphonate powder for oral/rectal suspension (Sorbisterit) - treatment of hyperkalaemia Published 12 August 2013 Product Update calcium polystyrene sulphonate powder for oral/rectal suspension (Sorbisterit ® ) SMC No: (890/13) Stanningley Pharma Ltd 05 July 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised (...) as follows: ADVICE: following an abbreviated submission calcium polystyrene sulphonate powder (Sorbisterit ® ) is accepted for use within NHS Scotland. Indication under review: treatment of hyperkalaemia, in patients with acute and chronic renal insufficiency, including patients undergoing dialysis treatment. Sorbisterit ® provides an alternative to the existing proprietary product at a lower cost. The dose of Sorbisterit ® and the existing proprietary product differ as the strength of the active

Scottish Medicines Consortium2013

90. Alpha blockers v calcium blockers to increase spontaneous passage of renal calculi

Alpha blockers v calcium blockers to increase spontaneous passage of renal calculi BestBets: Alpha blockers v calcium blockers to increase spontaneous passage of renal calculi Alpha blockers v calcium blockers to increase spontaneous passage of renal calculi Report By: Alexander Stewart - 4th Year Medical Student Search checked by Craig Ferguson - Consultant in Emergency Medicine Institution: Manchester University Date Submitted: 11th July 2012 Date Completed: 17th April 2013 Last Modified (...) : 17th April 2013 Status: Green (complete) Three Part Question In [adult patients with urinary calculi] is [treatment with alpha receptor blockers superior to treatment with calcium channel antagonists] at [increasing the speed and success of spontaneous stone passage]? Clinical Scenario A 51 year old presents to A&E with loin pain and macroscopic haematuria and a diagnosis of renal calculi is made. The patient�s pain is adequately controlled and the decision is discharge with Medical Expulsive

BestBETS2013

91. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone

An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone 23051740 2012 12 28 2013 06 17 2016 12 15 1523-1755 83 1 2013 Jan Kidney international Kidney Int. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney (...) disease better than high-dose angiotensin II receptor blockade alone. 167-76 10.1038/ki.2012.326 The OSCAR study was a multicenter, prospective randomized open-label blinded end-point study of 1164 Japanese elderly hypertensive patients comparing the efficacy of angiotensin II receptor blocker (ARB) uptitration to an ARB plus calcium channel blocker (CCB) combination. In this prospective study, we performed prespecified subgroup analysis according to baseline estimated glomerular filtration rate (eGFR

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

92. Do calcium supplements increase the risk of myocardial infarction?

Do calcium supplements increase the risk of myocardial infarction? Do calcium supplements increase the risk of myocardial infarction? » Morsels of Evidence Search Evidence based medicine for general practitioners « » Mar 15 Do calcium supplements increase the risk of myocardial infarction? Categories: , , by Journal reference: Bolland M, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta (...) -analysis. BMJ 2010; 341: c3691 Link: Published: 30 July 2010 Evidence cookie says… Calcium supplements may increase the risk of myocardial infarction, but, there is substantial uncertainty in the estimate . For every 69 patients treated with calcium supplements for 5 years rather than placebo, there would be one extra myocardial infarction, i.e., the NNH is 69 (95% confidence interval is from about 30 to 1000). Using the precautionary principle , regular calcium supplements should be avoided unless

Morsels of Evidence2013

93. Mineral Trioxide Aggregate Superior to Calcium Hydroxide in Pulpotomized Primary Molars

Mineral Trioxide Aggregate Superior to Calcium Hydroxide in Pulpotomized Primary Molars UTCAT2415, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Mineral Trioxide Aggregate Superior to Calcium Hydroxide in Pulpotomized Primary Molars Clinical Question In pulpotomized primary dentition, does Mineral Trioxide Aggregate produce superior results as compared to Calcium Hydroxide? Clinical Bottom Line Mineral Trioxide (...) Aggregate yielded superior results when used in primary molars in both radiographic and clinical findings. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Liu/2011 17 children Randomized Controlled Trial Key results In the treatment primary molars with MTA, the success rate was 94.1% with crown discoloration being the common complaint. In primary molars treated with Calcium Hydroxide, internal root

UTHSCSA Dental School CAT Library2013

94. Backfilling of iliac crest defects with hydroxyapatite-calcium triphosphate biphasic compound: a prospective, randomized computed tomography and patient-based analysis

Backfilling of iliac crest defects with hydroxyapatite-calcium triphosphate biphasic compound: a prospective, randomized computed tomography and patient-based analysis 23168135 2013 02 06 2013 07 23 2016 11 25 1878-1632 13 1 2013 Jan The spine journal : official journal of the North American Spine Society Spine J Backfilling of iliac crest defects with hydroxyapatite-calcium triphosphate biphasic compound: a prospective, randomized computed tomography and patient-based analysis. 54-61 10.1016 (...) /j.spinee.2012.10.019 S1529-9430(12)01295-8 Hydroxyapatite-calcium triphosphate (HCT) biphasic compounds are known to be efficacious in filling bone voids. No large study to date has assessed their radiographic efficacy in iliac crest voids with computed tomography (CT) analysis at a 2-year follow-up. To assess whether backfilling iliac crest defects with HCT biphasic compound decreases donor site pain and what effect backfilling has on CT appearance of the donor ilium. Prospective

EvidenceUpdates2013

95. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation.

The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. The rate of bone mineral loss in ... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1990 ) Volume: 112 , Issue: 1 , Pages: 29-34 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To determine the rate of bone loss in normal men, and to examine the effects of dietary (...) calcium and cholecalciferol supplementation on bone loss in men. DESIGN: Double-blinded, placebo-controlled 3-year trial of supplementation with calcium (1000 mg/d) and cholecalciferol (25 micrograms/d). SETTING: Clinical research center at a university medical facility. SUBJECTS: Normal men 30 to 87 years old, recruited from the Portland community. MEASUREMENTS AND MAIN RESULTS: Radial bone mineral content (assessed by single-photon absorptiometry) fell by 1.0%/y (95% CI, -1.3% to 0.7%) at a proximal

Annals of Internal Medicine2013

96. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism.

Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Effects of dichloromethylene diph... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1981 ) Volume: 95 , Issue: 1 , Pages: 23-27 PubMed: Available from or Find this paper at: Abstract Dichloromethylene diphosphonate (Cl2MDP), an inhibitor of osteoclast function, was evaluated for its (...) ability to lower the serum and urinary calcium in 14 patients with primary hyperparathyroidism. The study was double-blind, placebo-controlled, and cross-over in design. All patients received 12 weeks of Cl2MDP (1600 mg daily) and 12 weeks of placebo in a randomized sequence. The average serum calcium was lowered by Cl2MDP from 11.5 0.1 mg/dL to 10.8 0.2 mg/dL (p less than 0.001). In the 3-month follow-up after drug administration, the average serum calcium (11.0 0.2 mg/dL) remained significantly

Annals of Internal Medicine2013

97. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment.

Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Elimination of coincident Staphyl... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1991 ) Volume: 114 , Issue: 2 , Pages: 101-106 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To determine the safety and efficacy of mupirocin calcium (...) intranasally for 5 days, mupirocin calcium ointment is safe and effective in eliminating S. aureus nasal carriage in healthy persons for up to 3 months and appears to have a corresponding effect on hand carriage at 72 hours after therapy. Related papers B N Doebbeling , D L Breneman , H C Neu , R Aly , B G Yangco , H P Holley , et al. in Clinical Infectious Diseases (1993) 2 readers B N Doebbeling in Journal of chemotherapy Florence Italy (1994) 1 reader D L Holton , L E Nicolle , D Diley , K Bernstein

Annals of Internal Medicine2013

98. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss.

Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Calcium supplementation with and ... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1991 ) Volume: 115 , Issue: 2 , Pages: 505-512 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To determine whether augmentation of dietary calcium is effective in the prevention (...) of early postmenopausal bone loss. DESIGN: Three-arm, placebo-controlled, randomized parallel trial. The study duration was 2.9 1.1 (SD) years. SETTING: General community. PARTICIPANTS: 118 healthy, white women 3 to 6 years after spontaneous menopause, recruited by community announcement. INTERVENTIONS: Random allocation to daily intake of 1700 mg of calcium (calcium carbonate given in divided doses with meals); placebo; or conjugated equine estrogens (0.625 mg; days 1 to 25), progesterone (10 mg; days

Annals of Internal Medicine2013

99. Vitamin D and Calcium Supplementation to Prevent Fractures in Adults: U.S. Preventive Services Task Force Recommendation Statement.

Vitamin D and Calcium Supplementation to Prevent Fractures in Adults: U.S. Preventive Services Task Force Recommendation Statement. DESCRIPTION: New U.S. Preventive Services Task Force (USPSTF) recommendation statement on vitamin D and calcium supplementation to prevent fractures in adults. METHODS: The USPSTF commissioned 2 systematic evidence reviews and a meta-analysis on vitamin D supplementation with or without calcium to assess the effects of supplementation on bone health outcomes (...) in community-dwelling adults, the association of vitamin D and calcium levels with bone health outcomes, and the adverse effects of supplementation. POPULATION: These recommendations apply to noninstitutionalized or community-dwelling asymptomatic adults without a history of fractures. This recommendation does not apply to the treatment of persons with osteoporosis or vitamin D deficiency. RECOMMENDATION: The USPSTF concludes that the current evidence is insufficient to assess the balance of the benefits

Annals of Internal Medicine2013

100. Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study.

Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study. OBJECTIVE: To investigate the association between long term intake of dietary and supplemental calcium and death from all causes and cardiovascular disease. DESIGN: Prospective longitudinal cohort study. SETTING: Swedish mammography cohort, a population based cohort established in 1987-90. PARTICIPANTS: 61 433 women (born between 1914 and 1948) followed-up (...) for a median of 19 years. MAIN OUTCOME MEASURES: Primary outcome measures, identified from registry data, were time to death from all causes (n=11 944) and cause specific cardiovascular disease (n=3862), ischaemic heart disease (n=1932), and stroke (n=1100). Diet was assessed by food frequency questionnaires at baseline and in 1997 for 38 984 women, and intakes of calcium were estimated. Total calcium intake was the sum of dietary and supplemental calcium. RESULTS: The risk patterns with dietary calcium

BMJ2013 Full Text: Link to full Text with Trip Pro